Device Trial Radar · NCT07798726
TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
565
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Dec 31, 2031
Study completion Dec 31, 2035
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.
Conditions
- Mitral Valve Disease
- Mitral Annulus Calcification
- Mitral Regurgitation
- Mitral Stenosis
- Mitral Valve (MV) Regurgitation
- Mitral Valve Replacement
- Transcatheter Valve Replacement
- Mitral Valve Insufficiency
- Heart Valve Disease
Interventions
Cephea Mitral Valve SystemDevice
During the transcatheter mitral valve replacement procedure, the Cephea Mitral Valve will be placed via transseptal approach
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: 12 months post index procedure.
- Primary Safety EndpointTime frame: 30 days post index procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ascension Via Christi Hospitals Wichita
Wichita, Kansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.